Company Description
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel.
The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products.
It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Country | Israel |
| Founded | 1997 |
| IPO Date | Jan 23, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Alon Seri-Levy |
Contact Details
Address: 7 Golda Meir Street, Weizmann Science Park Ness Ziona, 7403650 Israel | |
| Phone | 972 8 931 3433 |
| Website | sol-gel.com |
Stock Details
| Ticker Symbol | SLGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001684693 |
| CUSIP Number | M8694L103 |
| ISIN Number | IL0011417206 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alon Seri-Levy | Co-Founder, Chief Executive Officer and Director |
| Dr. Itzik Yosef | Chief Operating Officer |
| Gilad Mamlok | Advisor |
| Moshe Arkin | Executive Chairman of the Board |
| Prof. David Avnir | Co-Founder |
| Eyal Ben-Or | Chief Financial Officer |
| Tamar Fishman Jutkowitz | Vice President and General Counsel |
| Dr. Karine Neimann | Vice President of Projects and Planning and Chief Chemist |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2024 | 424B3 | Prospectus |
| Nov 15, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | 6-K | Report of foreign issuer |
| Sep 25, 2024 | 6-K | Report of foreign issuer |
| Aug 27, 2024 | 6-K | Report of foreign issuer |
| Aug 19, 2024 | 424B3 | Prospectus |
| Aug 19, 2024 | 6-K/A | Filing |